Ironwood Licenses CNS Drug In $345M Deal with Bionomics
Proving that Ironwood Pharmaceuticals Inc. seeks to grow its pipeline beyond promising irritable bowel syndrome drug linaclotide, the Cambridge, Mass.-based firm picked up rights to a Phase I-stage anti-anxiety compound from Bionomics Ltd. in a deal valued at up to $345 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST